Acute Porphyria Drug Database

J07AH07 - Meningococcus C, Purified Polysaccharides Antigen Conjugated
Propably not porphyrinogenic
PNP

Important Information
In general, vaccines are regarded safe since such substance is not suspected to give an up-regulation of the heme biosynthesis as a direct effect. However, some vaccines can lead to a reaction with high fever persisting over days as a side effect. It is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to. Vigilance is therefore motivated when administrating a vaccine known to cause reactions with fever
Side effects
Fever is reported as a very common side effect the meningococcus C vaccine. A common adverse reaction of the vaccine that can be confused with an acute porphyric attack is nausea. This side effect may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
The active substances in the meningococcus C vaccine are conjugates of protein and oligosaccharides and with regards to its pharmacokinetics it has no conceivable porphyrinogenic effects.
Chemical description
The meningococcus C, purified polysaccharides antigen conjugated vaccine is composed of a meningococcal group C polysaccharide conjugated to a tetanus toxoid protein, a chemically detoxified form of tetanus toxin, adsorbed onto aluminum hydroxide (Pfizer, product monograph)
Therapeutic characteristics
The meningococcus C vaccine is indicated for active immunization in children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. It is administered by intramuscular injection. In children and adults one dose is sufficient while infants may need two or three doses.
Metabolism and pharmacokinetics
The meningococcus C vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015) #1860
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). NeisVac-C. (Last edition: April.2015). #1862
  5. Other sources
  6. Pfizer Canada. Product monograph. NeisVac-C® Vaccine www.pfizer.ca (31.03.2015) #1861

Similar drugs
Explore alternative drugs in similar therapeutic classes J07A / J07AH or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙